Tristel, the Suffolk based provider of infection and contamination control products, announced that its licensing agreement with The Clorox Company has been terminated. The agreement, which commenced in September 2009, focused on licensing Tristel’s proprietary chlorine dioxide product chemistry to Clorox for use in the US hospital surfaces disinfection market (the agreement did not cover Tristel's other hospital cleaning product areas such as endoscopy and ultrasound).

Tristel had assumed no royalty income would be earned until 2015-16 at the earliest from the deal and the termination will have no impact on the current year or following year's financial results. Tristel is now considering how to use the knowledge from the collaboration on the US market and its regulatory environment.

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here